The hGH fused with the synthetic polypeptide XTENTM (Schellenberger et al., 2009) (hGH-XTEN) is undergoing a Phase II clinical trial as monthly administration for the treatment of hGH deficiency. Here, GH1 is linked to hyperinsulinemic hypoglycemia, familial, 4.